Align Technology ALGN NASDAQ · Healthcare · United States
$168.32 +0.81% +$1.35
Summary
69 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $1.14B against $146.5M.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 12 USD is left as net profit.
- It bought back its own shares for $465.9M in the last fiscal year, 4.0% of its market value.
What to watch
- Revenue growth is slowing: 2.6% a year over the last 3 years against 10% over 5 years.
- The price moves much more than the market (beta 1.74).
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 23.9 USD for 1 USD of yearly profit. Over the last five years it was 45.1 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 10% a year over 5 years. Over the last 3 years it grew by 2.6% a year. For the next fiscal year analysts expect revenue to grow by 2.2%. Earnings per share grew by 7.0% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 32 USD
- Research and development 9.1 USD
- Sales and administration 43 USD
- Taxes and other 3.2 USD
- Net profit 12 USD
Net profit, industry median (Medical - Devices) 6.7 USD
Out of every 100 USD of revenue, 12 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 22
- Hold 9
- Sell 2
Today's price within the analysts' price targets
The average target of $192.5 is 14% above today's price. 67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Clear Aligner 80%
- Scanners And Services 20%
By region
- UNITED STATES 41%
- Other International 36%
- SWITZERLAND 23%
Clear Aligner brings in 80% of revenue. Scanners And Services grew fastest, by 2.9% a year.
Segments in detail